CIDRAP44m
FDA approves combination antibiotic for difficult-to-treat infections
Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment options.
PharmiWeb11h
Pharmaceutical Market: Shaping the Future of Healthcare and Medicine
Pharmaceutical Market Size and Growth 2025 to 2034The global pharmaceutical market size was valued at USD 1,607.07 billion in ...
CVM: Fiscal Year 2024 Results
CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) reports fiscal year 2024 financial and operational ...
JD Supra3d
EU Biosimilar Regulatory and Launch Updates
CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...
Fact Check: Moderna began clinical trials of COVID vaccine in 2020, not 2017
Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
Europe Digital Therapeutics Market Research Report 2025-2030: Dominated by Mindable Health, Cara Care, Kaia Health Software, HealthHero, and GAIA
Presents Shares and Growth Trends for Germany, France, United Kingdom, Italy, Spain, Russia, Poland, Bulgaria, Finland, and ...
Rising to the challenge of selling vaccines in Trumpworld
For now, her focus is on making the most of its existing portfolio, notably Keytruda – the world’s top-selling cancer drug – ...
Center for Biosimilars3d
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...